LAUSR

SLS COPD (NCT01551758) was a 12-month, open-label, randomised controlled trial (RCT) that evaluated the effectiveness and safety of initiating fluticasone furoate/vilanterol 100/25µg vs continuing usual care in COPD patients (pts) with exacerbation (Exa) history (Vestbo et al. NEJM 2016). This was the first effectiveness RCT of its kind in UK primary care with broad inclusion criteria and minimal disruption to routine clinical care. The non-interventional ACCESS study (NCT01516528) examined the rate of mod/sev COPD Exa in primary care pts in 6 European countries (GSK Study 115058). The current study describes similarities and differences between SLS COPD and ACCESS datasets. Demographics/clinical characteristics of SLS COPD and ACCESS pts were recorded either at study screening or after randomisation. SLS COPD entry criteria included ≥1 Exa in the preceding 3 yrs. Pt demographics and clinical characteristics in SLS COPD and ACCESS are shown (Table). SLS COPD pts had a higher Exa rate and higher CAT scores than ACCESS pts. Other variables were broadly similar between SLS COPD and ACCESS, and across countries. SLS COPD pts were more severely impacted than ACCESS pts, possibly due to the Exa history inclusion criterion. Otherwise, pt characteristics were largely similar between the UK SLS COPD study and the European countries in the ACCESS population. Funding by GSK: studies 115151 and 115058.